Extended Release Guanfacine in Pediatric Anxiety Disorders: A Pilot, Randomized, Placebo-Controlled Trial.
-
Authors
-
-
Strawn, Jeffrey R1
-
Compton, Scott N2
-
Robertson, Brigitte3
-
Albano, Anne Marie4
-
Hamdani, Mohamed3
-
Rynn, Moira A5
-
1
1 Anxiety Disorders Research Program, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine , Cincinnati, Ohio.
-
2
2 Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine , Durham, North Carolina.
-
3
3 Shire , Lexington, Massachusetts.
-
4
4 New York State Psychiatric Institute, Columbia University , New York, New York.
-
5
5 New York Presbyterian Morgan Stanley Children's Hospital, Columbia University/New York State Psychiatric Institute, New York, New York.
- Type
- Published Article
- Journal
-
Journal of Child and Adolescent Psychopharmacology
- Publisher
-
Mary Ann Liebert
- Publication Date
-
Feb 06, 2017
- Identifiers
-
DOI: 10.1089/cap.2016.0132
-
PMID: 28165762
- Source
-
Medline
- Keywords
-
- License
-
Unknown
Abstract
GXR was well tolerated in pediatric subjects with GAD, SAD, and/or social anxiety disorder. ClinicalTrials.gov Identifier: NCT01470469.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 07/07/2017 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/28165762
Report this publication